Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 18159061)

1.

Genetic testing in diverse populations: are researchers doing enough to get out the correct message?

Huo D, Olopade OI.

JAMA. 2007 Dec 26;298(24):2910-1. No abstract available.

PMID:
18159061
2.

Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups.

John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, West DW, Whittemore AS.

JAMA. 2007 Dec 26;298(24):2869-76.

PMID:
18159056
3.

Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.

Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI.

JAMA. 2005 Oct 19;294(15):1925-33.

PMID:
16234499
4.

Caution in generalizing known genetic risk markers for breast cancer across all ethnic/racial populations.

Chen F, Stram DO, Le Marchand L, Monroe KR, Kolonel LN, Henderson BE, Haiman CA.

Eur J Hum Genet. 2011 Feb;19(2):243-5. doi: 10.1038/ejhg.2010.185. Epub 2010 Nov 24.

5.

Frequency of the cholesteryl ester storage disease common LIPA E8SJM mutation (c.894G>A) in various racial and ethnic groups.

Scott SA, Liu B, Nazarenko I, Martis S, Kozlitina J, Yang Y, Ramirez C, Kasai Y, Hyatt T, Peter I, Desnick RJ.

Hepatology. 2013 Sep;58(3):958-65. doi: 10.1002/hep.26327. Epub 2013 Jul 29.

6.

Promising test flags BRCA mutations in populations of Hispanic women.

Voelker R.

JAMA. 2009 Apr 1;301(13):1326-7. doi: 10.1001/jama.2009.403. No abstract available.

PMID:
19336700
7.
8.

Genetic susceptibility testing: a therapeutic illusion?--reply.

Rosner F.

Cancer. 1998 Jan 1;82(1):232-4. No abstract available.

PMID:
9428505
9.

Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort.

Cheng I, Penney KL, Stram DO, Le Marchand L, Giorgi E, Haiman CA, Kolonel LN, Pike M, Hirschhorn J, Henderson BE, Freedman ML.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1993-7.

10.

Ashkenazi Jews and breast cancer: the consequences of linking ethnic identity to genetic disease.

Brandt-Rauf SI, Raveis VH, Drummond NF, Conte JA, Rothman SM.

Am J Public Health. 2006 Nov;96(11):1979-88. Epub 2006 Oct 3.

11.

Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States.

Huo D, Senie RT, Daly M, Buys SS, Cummings S, Ogutha J, Hope K, Olopade OI.

J Clin Oncol. 2009 Mar 10;27(8):1184-90. doi: 10.1200/JCO.2008.17.5869. Epub 2009 Feb 2. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262.

12.

The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.

Gal I, Gershoni Baruch R, Haber D, Dagan E, Eisenberg-Barzilai S, Zidan J, Friedman E.

Fam Cancer. 2004;3(1):11-4.

PMID:
15131400
13.

The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim.

Bar-Sade RB, Kruglikova A, Modan B, Gak E, Hirsh-Yechezkel G, Theodor L, Novikov I, Gershoni-Baruch R, Risel S, Papa MZ, Ben-Baruch G, Friedman E.

Hum Mol Genet. 1998 May;7(5):801-5.

14.

Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2.

Neuhausen SL, Ostrander EA.

Genet Test. 1997;1(2):75-83. Review.

PMID:
10464630
15.

Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.

Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG; Northwestern Cancer Genetics Group.

Cancer. 2014 May 15;120(10):1557-64. doi: 10.1002/cncr.28577. Epub 2014 Feb 12.

PMID:
24522996
16.

Cancer. A risky business--assessing breast cancer risk.

Levy-Lahad E, Plon SE.

Science. 2003 Oct 24;302(5645):574-5. No abstract available.

PMID:
14576407
17.

The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467-73.

18.

Two BRCA1/2 founder mutations in Jews of Sephardic origin.

Sagi M, Eilat A, Ben Avi L, Goldberg Y, Bercovich D, Hamburger T, Peretz T, Lerer I.

Fam Cancer. 2011 Mar;10(1):59-63. doi: 10.1007/s10689-010-9395-9.

PMID:
21063910
19.

Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.

Haiman CA, Garcia RR, Hsu C, Xia L, Ha H, Sheng X, Le Marchand L, Kolonel LN, Henderson BE, Stallcup MR, Greene GL, Press MF.

BMC Cancer. 2009 Jan 30;9:43. doi: 10.1186/1471-2407-9-43.

20.

The multiethnic cohort study: exploring genes, lifestyle and cancer risk.

Kolonel LN, Altshuler D, Henderson BE.

Nat Rev Cancer. 2004 Jul;4(7):519-27. Review. No abstract available.

PMID:
15229477
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk